Business Wire10.17.19
Cala Health Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, has named Renee Ryan as CEO. Ryan has been appointed to build on the company’s scientific progress and lead its operations and commercialization strategy to support the next phase of growth. Founder and current CEO Kate Rosenbluth will continue to lead in the role of founder and chief scientific officer and serve on the company's Board of Directors.
Ryan brings over 20 years of experience building category-creating healthcare companies. She most recently served as vice president, Venture Investments, at Johnson & Johnson Innovation (JJDC). There, she led over 16 new investments, including Cala Health’s Series A funding, and created five strategic NewCos. Ryan has been a member of Cala Health’s board since the company’s inception in 2014. Prior to her leadership at JJDC, Ryan was a healthcare investment banker at R.W. Baird, Jefferies, and Goldman Sachs.
“I have long admired Kate’s scientific prowess and am excited by the near-term potential of Cala TrioTM for essential tremor, as well as our bioelectronic non-invasive neuromodulation platform for multiple chronic diseases,” said Ryan. “I’m thrilled and proud to see the swift trajectory of the company, including the recent $50 million Series C funding, and the phased launch of Cala Trio in the United States. I look forward to working with Kate and the talented team at Cala Health to maintain this momentum as we transition to a commercial organization.”
Rosenbluth will oversee research focused on advancing the company’s pipeline in neurology, cardiology, and psychiatry. She will also lead collaborations with influential academic medical centers and provide evidence-based scientific support for clinical adoption of the company’s neuromodulation platforms.
“I’m very pleased to partner with Renee to fuel the healthy growth and expansion of Cala Health,” Rosenbluth said. “Moreover, I’m excited to continue advancing our new products and realizing our vision to transform the standard of care for chronic disease with neuromodulation therapies.”
Cala Health is a bioelectronic medicine company whose wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is essential tremor, a disease experienced by more than 7 million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
Ryan brings over 20 years of experience building category-creating healthcare companies. She most recently served as vice president, Venture Investments, at Johnson & Johnson Innovation (JJDC). There, she led over 16 new investments, including Cala Health’s Series A funding, and created five strategic NewCos. Ryan has been a member of Cala Health’s board since the company’s inception in 2014. Prior to her leadership at JJDC, Ryan was a healthcare investment banker at R.W. Baird, Jefferies, and Goldman Sachs.
“I have long admired Kate’s scientific prowess and am excited by the near-term potential of Cala TrioTM for essential tremor, as well as our bioelectronic non-invasive neuromodulation platform for multiple chronic diseases,” said Ryan. “I’m thrilled and proud to see the swift trajectory of the company, including the recent $50 million Series C funding, and the phased launch of Cala Trio in the United States. I look forward to working with Kate and the talented team at Cala Health to maintain this momentum as we transition to a commercial organization.”
Rosenbluth will oversee research focused on advancing the company’s pipeline in neurology, cardiology, and psychiatry. She will also lead collaborations with influential academic medical centers and provide evidence-based scientific support for clinical adoption of the company’s neuromodulation platforms.
“I’m very pleased to partner with Renee to fuel the healthy growth and expansion of Cala Health,” Rosenbluth said. “Moreover, I’m excited to continue advancing our new products and realizing our vision to transform the standard of care for chronic disease with neuromodulation therapies.”
Cala Health is a bioelectronic medicine company whose wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is essential tremor, a disease experienced by more than 7 million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
